Business
-
Insilico Medicine, which claims to be “a generative artificial intelligence (AI)-driven clinical-stage drug discovery company,” said that it is “the first AI drug discovery company to venture into nebulized formulations” as the company plans to… Read more . . .
-
Lupin announced that its German subsidiary Hormosan Pharma has launched Luforbec beclometasone / formoterol MDI for the treatment of asthma and COPD in Germany. According to Lupin, the price of the MDI, which is a generic… Read more . . .
-
Altamira Therapeutics announced that Pharma Nordic will market and distribute Bentrio bentonite-based OTC nasal spray for protection against allergens in Norway as part of a deal that could potentially expand to include Sweden, Finland, and Denmark,… Read more . . .
-
Advent Therapeutics announced that the company has received a $3 million Small Business Innovation Research (SBIR) Phase 2B grant from the National Institutes of Health for continued development of the company’s inhaled vitamin A (retinol)… Read more . . .
-
H&T Presspart will expand cleanroom facilities and add a new production line to manufacture Kindeva Drug Delivery‘s dose counters and dose indicators for use in Chiesi MDIs, the companies have announced. According to the announcement,… Read more . . .
-
Health Canada announced that Pharmascience’s Pendopharm division is recalling one lot of Rhinaris Nasal Mist saline nasal spray after “testing showed that the preservative in the product may not be as effective as expected.” Specifically,… Read more . . .
-
Cipla US has announced a voluntary recall of 6 batches of albuterol MDIs after a report of valve leakage in a single inhaler manufactured in November 2021. The company said that no adverse events have been… Read more . . .
-
MannKind Corporation has filed a notice with the US Securities and Exchange Commission (SEC) stating that manufacturing of clinical trial supplies for its planned Phase 2/3 study of MNKD-101 clofazimine inhalation suspension in patients with… Read more . . .
-
Liquidia Corporation will pay Pharmosa Biopharm $10 million up front plus development and sales milestones worth up to $215 million and royalties on potential sales for North American development and commercialization rights to Pharmosa’s L606 liposomal… Read more . . .
-
Orion Pharmaceuticals has announced plans for a €30 million expansion of its production facility in Espoo, Finland, including a new filling line for its Easyhaler dry powder inhalers. The company said that it is responding… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan